Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2024-2032
The global radiodermatitis market size reached US$ 499.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 660.3 Million by 2032, exhibiting a growth rate (CAGR) of 3.06% during 2024-2032.
Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.
Radiodermatitis Market Trends:
The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and distribution channel.
Breakup by Product:
Topical
Corticosteroids
Hydrophilic Creams
Antibiotics
Others
Oral
Dressings
Hydrogel and Hydrocolloid Dressings
No Sting Barrier Film
Honey Impregnated Gauze
Silicone Coated Dressings
Others
Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mцlnlycke Health Care AB and Stratpharma AG.
Key Questions Answered in This Report
1. What was the size of the global radiodermatitis market in 2023?
2. What is the expected growth rate of the global radiodermatitis market during 2024-2032?
3. What has been the impact of COVID-19 on the global radiodermatitis market?
4. What are the key factors driving the global radiodermatitis market?
5. What is the breakup of the global radiodermatitis market based on the product?
6. What is the breakup of the global radiodermatitis market based on the distribution channel?
7. What are the key regions in the global radiodermatitis market?
8. Who are the key players/companies in the global radiodermatitis market?
Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.
Radiodermatitis Market Trends:
The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and distribution channel.
Breakup by Product:
Topical
Corticosteroids
Hydrophilic Creams
Antibiotics
Others
Oral
Dressings
Hydrogel and Hydrocolloid Dressings
No Sting Barrier Film
Honey Impregnated Gauze
Silicone Coated Dressings
Others
Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mцlnlycke Health Care AB and Stratpharma AG.
Key Questions Answered in This Report
1. What was the size of the global radiodermatitis market in 2023?
2. What is the expected growth rate of the global radiodermatitis market during 2024-2032?
3. What has been the impact of COVID-19 on the global radiodermatitis market?
4. What are the key factors driving the global radiodermatitis market?
5. What is the breakup of the global radiodermatitis market based on the product?
6. What is the breakup of the global radiodermatitis market based on the distribution channel?
7. What are the key regions in the global radiodermatitis market?
8. Who are the key players/companies in the global radiodermatitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL RADIODERMATITIS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT
6.1 Topical
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Corticosteroids
6.1.2.2 Hydrophilic Creams
6.1.2.3 Antibiotics
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Oral
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Dressings
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Hydrogel and Hydrocolloid Dressings
6.3.2.2 No Sting Barrier Film
6.3.2.3 Honey Impregnated Gauze
6.3.2.4 Silicone Coated Dressings
6.3.2.5 Others
6.3.3 Market Forecast
7 MARKET BREAKUP BY DISTRIBUTION CHANNEL
7.1 Hospital Pharmacy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacy
7.3.1 Market Trends
7.3.2 Market Forecast
8 MARKET BREAKUP BY REGION
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT ANALYSIS
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 VALUE CHAIN ANALYSIS
11 PORTERS FIVE FORCES ANALYSIS
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 PRICE ANALYSIS
13 COMPETITIVE LANDSCAPE
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 3M Company
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Bausch Health Companies Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Bayer AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 BMG PHARMA S.p.A.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.5 Charles River Laboratories International Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 ConvaTec Group plc
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.7 Helsinn Healthcare SA
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.8 ICON plc
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Integra LifeSciences
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Mцlnlycke Health Care AB
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 SWOT Analysis
13.3.11 Stratpharma AG
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL RADIODERMATITIS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT
6.1 Topical
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Corticosteroids
6.1.2.2 Hydrophilic Creams
6.1.2.3 Antibiotics
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Oral
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Dressings
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Hydrogel and Hydrocolloid Dressings
6.3.2.2 No Sting Barrier Film
6.3.2.3 Honey Impregnated Gauze
6.3.2.4 Silicone Coated Dressings
6.3.2.5 Others
6.3.3 Market Forecast
7 MARKET BREAKUP BY DISTRIBUTION CHANNEL
7.1 Hospital Pharmacy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacy
7.3.1 Market Trends
7.3.2 Market Forecast
8 MARKET BREAKUP BY REGION
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT ANALYSIS
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 VALUE CHAIN ANALYSIS
11 PORTERS FIVE FORCES ANALYSIS
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 PRICE ANALYSIS
13 COMPETITIVE LANDSCAPE
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 3M Company
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Bausch Health Companies Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Bayer AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 BMG PHARMA S.p.A.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.5 Charles River Laboratories International Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 ConvaTec Group plc
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.7 Helsinn Healthcare SA
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.8 ICON plc
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Integra LifeSciences
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Mцlnlycke Health Care AB
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 SWOT Analysis
13.3.11 Stratpharma AG
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
